Global Dendritic Cell Cancer Vaccine Immunotherapy Supply, Demand and Key Producers, 2024-2030

Description

The global Dendritic Cell Cancer Vaccine Immunotherapy market size is expected to reach $ 1220.9 million by 2030, rising at a market growth of 9.7% CAGR during the forecast period (2024-2030).

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Dendritic cells (DCs) are one of the major antigen-presenting cells found in lymphoid organs. Main function of the dendritic cells is antigen display and activation of T-cells. Antigen display presents the identity of pathogen to T-cells for their identification and elimination from the body. These cells have proficiency of capturing and processing tumor antigens, which activates expression of lymphocyte co-stimulatory molecules. Consequently, it results in secretion of cytokines to initiate immune response. Over 60 dendritic cell and tumor cell cancer vaccines are currently in clinical / preclinical stages of development; 70% of the pipeline comprises of dendritic cell cancer vaccines.

This report studies the global Dendritic Cell Cancer Vaccine Immunotherapy demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Dendritic Cell Cancer Vaccine Immunotherapy, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Dendritic Cell Cancer Vaccine Immunotherapy that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Dendritic Cell Cancer Vaccine Immunotherapy total market, 2019-2030, (USD Million)
Global Dendritic Cell Cancer Vaccine Immunotherapy total market by region & country, CAGR, 2019-2030, (USD Million)
U.S. VS China: Dendritic Cell Cancer Vaccine Immunotherapy total market, key domestic companies and share, (USD Million)
Global Dendritic Cell Cancer Vaccine Immunotherapy revenue by player and market share 2019-2024, (USD Million)
Global Dendritic Cell Cancer Vaccine Immunotherapy total market by Type, CAGR, 2019-2030, (USD Million)
Global Dendritic Cell Cancer Vaccine Immunotherapy total market by Application, CAGR, 2019-2030, (USD Million).

This reports profiles major players in the global Dendritic Cell Cancer Vaccine Immunotherapy market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lineage Cell Therapeutics, AVAX Technologies, DCPrime, Gradalis, Heat Biologics, ImmunoCellular Therapeutics, Immunicum, MolecuVax and Northwest Biotherapeutics, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Dendritic Cell Cancer Vaccine Immunotherapy market.

Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.

Global Dendritic Cell Cancer Vaccine Immunotherapy Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Segmentation by Type
    Provenge
    Apceden
    CreaVax
    Others

Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Segmentation by Application
    Pediatrics
    Adults

Companies Profiled:
    Lineage Cell Therapeutics
    AVAX Technologies
    DCPrime
    Gradalis
    Heat Biologics
    ImmunoCellular Therapeutics
    Immunicum
    MolecuVax
    Northwest Biotherapeutics
    Pique Therapeutics
    Regeneus
    Tessa Therapeutics
    Vaccinogen
    XEME Biopharma

Key Questions Answered
1. How big is the global Dendritic Cell Cancer Vaccine Immunotherapy market?
2. What is the demand of the global Dendritic Cell Cancer Vaccine Immunotherapy market?
3. What is the year over year growth of the global Dendritic Cell Cancer Vaccine Immunotherapy market?
4. What is the total value of the global Dendritic Cell Cancer Vaccine Immunotherapy market?
5. Who are the major players in the global Dendritic Cell Cancer Vaccine Immunotherapy market?

Table of Contents

1 Supply Summary
    1.1 Dendritic Cell Cancer Vaccine Immunotherapy Introduction
    1.2 World Dendritic Cell Cancer Vaccine Immunotherapy Market Size & Forecast (2019 & 2023 & 2030)
    1.3 World Dendritic Cell Cancer Vaccine Immunotherapy Total Market by Region (by Headquarter Location)
        1.3.1 World Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2019-2030), (by Headquarter Location)
        1.3.2 United States Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2019-2030)
        1.3.3 China Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2019-2030)
        1.3.4 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2019-2030)
        1.3.5 Japan Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2019-2030)
        1.3.6 South Korea Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2019-2030)
        1.3.7 ASEAN Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2019-2030)
        1.3.8 India Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2019-2030)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Dendritic Cell Cancer Vaccine Immunotherapy Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Dendritic Cell Cancer Vaccine Immunotherapy Major Market Trends

2 Demand Summary
    2.1 World Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2019-2030)
    2.2 World Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Region
        2.2.1 World Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Region (2019-2024)
        2.2.2 World Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Forecast by Region (2025-2030)
    2.3 United States Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2019-2030)
    2.4 China Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2019-2030)
    2.5 Europe Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2019-2030)
    2.6 Japan Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2019-2030)
    2.7 South Korea Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2019-2030)
    2.8 ASEAN Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2019-2030)
    2.9 India Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2019-2030)

3 World Dendritic Cell Cancer Vaccine Immunotherapy Companies Competitive Analysis
    3.1 World Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Player (2019-2024)
    3.2 Industry Rank and Concentration Rate (CR)
        3.2.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Industry Rank of Major Players
        3.2.2 Global Concentration Ratios (CR4) for Dendritic Cell Cancer Vaccine Immunotherapy in 2023
        3.2.3 Global Concentration Ratios (CR8) for Dendritic Cell Cancer Vaccine Immunotherapy in 2023
    3.3 Dendritic Cell Cancer Vaccine Immunotherapy Company Evaluation Quadrant
    3.4 Dendritic Cell Cancer Vaccine Immunotherapy Market: Overall Company Footprint Analysis
        3.4.1 Dendritic Cell Cancer Vaccine Immunotherapy Market: Region Footprint
        3.4.2 Dendritic Cell Cancer Vaccine Immunotherapy Market: Company Product Type Footprint
        3.4.3 Dendritic Cell Cancer Vaccine Immunotherapy Market: Company Product Application Footprint
    3.5 Competitive Environment
        3.5.1 Historical Structure of the Industry
        3.5.2 Barriers of Market Entry
        3.5.3 Factors of Competition
    3.6 Mergers, Acquisitions Activity

4 United States VS China VS Rest of the World (by Headquarter Location)
    4.1 United States VS China: Dendritic Cell Cancer Vaccine Immunotherapy Revenue Comparison (by Headquarter Location)
        4.1.1 United States VS China: Dendritic Cell Cancer Vaccine Immunotherapy Market Size Comparison (2019 & 2023 & 2030) (by Headquarter Location)
        4.1.2 United States VS China: Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share Comparison (2019 & 2023 & 2030)
    4.2 United States Based Companies VS China Based Companies: Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Comparison
        4.2.1 United States VS China: Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Comparison (2019 & 2023 & 2030)
        4.2.2 United States VS China: Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Market Share Comparison (2019 & 2023 & 2030)
    4.3 United States Based Dendritic Cell Cancer Vaccine Immunotherapy Companies and Market Share, 2019-2024
        4.3.1 United States Based Dendritic Cell Cancer Vaccine Immunotherapy Companies, Headquarters (States, Country)
        4.3.2 United States Based Companies Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (2019-2024)
    4.4 China Based Companies Dendritic Cell Cancer Vaccine Immunotherapy Revenue and Market Share, 2019-2024
        4.4.1 China Based Dendritic Cell Cancer Vaccine Immunotherapy Companies, Company Headquarters (Province, Country)
        4.4.2 China Based Companies Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (2019-2024)
    4.5 Rest of World Based Dendritic Cell Cancer Vaccine Immunotherapy Companies and Market Share, 2019-2024
        4.5.1 Rest of World Based Dendritic Cell Cancer Vaccine Immunotherapy Companies, Headquarters (States, Country)
        4.5.2 Rest of World Based Companies Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (2019-2024)

5 Market Analysis by Type
    5.1 World Dendritic Cell Cancer Vaccine Immunotherapy Market Size Overview by Type: 2019 VS 2023 VS 2030
    5.2 Segment Introduction by Type
        5.2.1 Provenge
        5.2.2 Apceden
        5.2.3 CreaVax
        5.2.4 Others
    5.3 Market Segment by Type
        5.3.1 World Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2019-2024)
        5.3.2 World Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2025-2030)
        5.3.3 World Dendritic Cell Cancer Vaccine Immunotherapy Market Size Market Share by Type (2019-2030)

6 Market Analysis by Application
    6.1 World Dendritic Cell Cancer Vaccine Immunotherapy Market Size Overview by Application: 2019 VS 2023 VS 2030
    6.2 Segment Introduction by Application
        6.2.1 Pediatrics
        6.2.2 Adults
    6.3 Market Segment by Application
        6.3.1 World Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2019-2024)
        6.3.2 World Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2025-2030)
        6.3.3 World Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2019-2030)

7 Company Profiles
    7.1 Lineage Cell Therapeutics
        7.1.1 Lineage Cell Therapeutics Details
        7.1.2 Lineage Cell Therapeutics Major Business
        7.1.3 Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Services
        7.1.4 Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        7.1.5 Lineage Cell Therapeutics Recent Developments/Updates
        7.1.6 Lineage Cell Therapeutics Competitive Strengths & Weaknesses
    7.2 AVAX Technologies
        7.2.1 AVAX Technologies Details
        7.2.2 AVAX Technologies Major Business
        7.2.3 AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Product and Services
        7.2.4 AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        7.2.5 AVAX Technologies Recent Developments/Updates
        7.2.6 AVAX Technologies Competitive Strengths & Weaknesses
    7.3 DCPrime
        7.3.1 DCPrime Details
        7.3.2 DCPrime Major Business
        7.3.3 DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Product and Services
        7.3.4 DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        7.3.5 DCPrime Recent Developments/Updates
        7.3.6 DCPrime Competitive Strengths & Weaknesses
    7.4 Gradalis
        7.4.1 Gradalis Details
        7.4.2 Gradalis Major Business
        7.4.3 Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Product and Services
        7.4.4 Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        7.4.5 Gradalis Recent Developments/Updates
        7.4.6 Gradalis Competitive Strengths & Weaknesses
    7.5 Heat Biologics
        7.5.1 Heat Biologics Details
        7.5.2 Heat Biologics Major Business
        7.5.3 Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Product and Services
        7.5.4 Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        7.5.5 Heat Biologics Recent Developments/Updates
        7.5.6 Heat Biologics Competitive Strengths & Weaknesses
    7.6 ImmunoCellular Therapeutics
        7.6.1 ImmunoCellular Therapeutics Details
        7.6.2 ImmunoCellular Therapeutics Major Business
        7.6.3 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Services
        7.6.4 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        7.6.5 ImmunoCellular Therapeutics Recent Developments/Updates
        7.6.6 ImmunoCellular Therapeutics Competitive Strengths & Weaknesses
    7.7 Immunicum
        7.7.1 Immunicum Details
        7.7.2 Immunicum Major Business
        7.7.3 Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Product and Services
        7.7.4 Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        7.7.5 Immunicum Recent Developments/Updates
        7.7.6 Immunicum Competitive Strengths & Weaknesses
    7.8 MolecuVax
        7.8.1 MolecuVax Details
        7.8.2 MolecuVax Major Business
        7.8.3 MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Product and Services
        7.8.4 MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        7.8.5 MolecuVax Recent Developments/Updates
        7.8.6 MolecuVax Competitive Strengths & Weaknesses
    7.9 Northwest Biotherapeutics
        7.9.1 Northwest Biotherapeutics Details
        7.9.2 Northwest Biotherapeutics Major Business
        7.9.3 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Services
        7.9.4 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        7.9.5 Northwest Biotherapeutics Recent Developments/Updates
        7.9.6 Northwest Biotherapeutics Competitive Strengths & Weaknesses
    7.10 Pique Therapeutics
        7.10.1 Pique Therapeutics Details
        7.10.2 Pique Therapeutics Major Business
        7.10.3 Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Services
        7.10.4 Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        7.10.5 Pique Therapeutics Recent Developments/Updates
        7.10.6 Pique Therapeutics Competitive Strengths & Weaknesses
    7.11 Regeneus
        7.11.1 Regeneus Details
        7.11.2 Regeneus Major Business
        7.11.3 Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Product and Services
        7.11.4 Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        7.11.5 Regeneus Recent Developments/Updates
        7.11.6 Regeneus Competitive Strengths & Weaknesses
    7.12 Tessa Therapeutics
        7.12.1 Tessa Therapeutics Details
        7.12.2 Tessa Therapeutics Major Business
        7.12.3 Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Services
        7.12.4 Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        7.12.5 Tessa Therapeutics Recent Developments/Updates
        7.12.6 Tessa Therapeutics Competitive Strengths & Weaknesses
    7.13 Vaccinogen
        7.13.1 Vaccinogen Details
        7.13.2 Vaccinogen Major Business
        7.13.3 Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Product and Services
        7.13.4 Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        7.13.5 Vaccinogen Recent Developments/Updates
        7.13.6 Vaccinogen Competitive Strengths & Weaknesses
    7.14 XEME Biopharma
        7.14.1 XEME Biopharma Details
        7.14.2 XEME Biopharma Major Business
        7.14.3 XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Product and Services
        7.14.4 XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
        7.14.5 XEME Biopharma Recent Developments/Updates
        7.14.6 XEME Biopharma Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Dendritic Cell Cancer Vaccine Immunotherapy Industry Chain
    8.2 Dendritic Cell Cancer Vaccine Immunotherapy Upstream Analysis
    8.3 Dendritic Cell Cancer Vaccine Immunotherapy Midstream Analysis
    8.4 Dendritic Cell Cancer Vaccine Immunotherapy Downstream Analysis

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Region (2019, 2023 and 2030) & (USD Million), (by Headquarter Location)
    Table 2. World Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Region (2019-2024) & (USD Million), (by Headquarter Location)
    Table 3. World Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Region (2025-2030) & (USD Million), (by Headquarter Location)
    Table 4. World Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Region (2019-2024), (by Headquarter Location)
    Table 5. World Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Region (2025-2030), (by Headquarter Location)
    Table 6. Major Market Trends
    Table 7. World Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Growth Rate Forecast by Region (2019 & 2023 & 2030) & (USD Million)
    Table 8. World Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value by Region (2019-2024) & (USD Million)
    Table 9. World Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Forecast by Region (2025-2030) & (USD Million)
    Table 10. World Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Player (2019-2024) & (USD Million)
    Table 11. Revenue Market Share of Key Dendritic Cell Cancer Vaccine Immunotherapy Players in 2023
    Table 12. World Dendritic Cell Cancer Vaccine Immunotherapy Industry Rank of Major Player, Based on Revenue in 2023
    Table 13. Global Dendritic Cell Cancer Vaccine Immunotherapy Company Evaluation Quadrant
    Table 14. Head Office of Key Dendritic Cell Cancer Vaccine Immunotherapy Player
    Table 15. Dendritic Cell Cancer Vaccine Immunotherapy Market: Company Product Type Footprint
    Table 16. Dendritic Cell Cancer Vaccine Immunotherapy Market: Company Product Application Footprint
    Table 17. Dendritic Cell Cancer Vaccine Immunotherapy Mergers & Acquisitions Activity
    Table 18. United States VS China Dendritic Cell Cancer Vaccine Immunotherapy Market Size Comparison, (2019 & 2023 & 2030) & (USD Million)
    Table 19. United States VS China Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Comparison, (2019 & 2023 & 2030) & (USD Million)
    Table 20. United States Based Dendritic Cell Cancer Vaccine Immunotherapy Companies, Headquarters (States, Country)
    Table 21. United States Based Companies Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (2019-2024) & (USD Million)
    Table 22. United States Based Companies Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share (2019-2024)
    Table 23. China Based Dendritic Cell Cancer Vaccine Immunotherapy Companies, Headquarters (Province, Country)
    Table 24. China Based Companies Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (2019-2024) & (USD Million)
    Table 25. China Based Companies Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share (2019-2024)
    Table 26. Rest of World Based Dendritic Cell Cancer Vaccine Immunotherapy Companies, Headquarters (States, Country)
    Table 27. Rest of World Based Companies Dendritic Cell Cancer Vaccine Immunotherapy Revenue, (2019-2024) & (USD Million)
    Table 28. Rest of World Based Companies Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share (2019-2024)
    Table 29. World Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type, (USD Million), 2019 & 2023 & 2030
    Table 30. World Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2019-2024) & (USD Million)
    Table 31. World Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2025-2030) & (USD Million)
    Table 32. World Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application, (USD Million), 2019 & 2023 & 2030
    Table 33. World Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2019-2024) & (USD Million)
    Table 34. World Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2025-2030) & (USD Million)
    Table 35. Lineage Cell Therapeutics Basic Information, Area Served and Competitors
    Table 36. Lineage Cell Therapeutics Major Business
    Table 37. Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Services
    Table 38. Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 39. Lineage Cell Therapeutics Recent Developments/Updates
    Table 40. Lineage Cell Therapeutics Competitive Strengths & Weaknesses
    Table 41. AVAX Technologies Basic Information, Area Served and Competitors
    Table 42. AVAX Technologies Major Business
    Table 43. AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Product and Services
    Table 44. AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 45. AVAX Technologies Recent Developments/Updates
    Table 46. AVAX Technologies Competitive Strengths & Weaknesses
    Table 47. DCPrime Basic Information, Area Served and Competitors
    Table 48. DCPrime Major Business
    Table 49. DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Product and Services
    Table 50. DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 51. DCPrime Recent Developments/Updates
    Table 52. DCPrime Competitive Strengths & Weaknesses
    Table 53. Gradalis Basic Information, Area Served and Competitors
    Table 54. Gradalis Major Business
    Table 55. Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Product and Services
    Table 56. Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 57. Gradalis Recent Developments/Updates
    Table 58. Gradalis Competitive Strengths & Weaknesses
    Table 59. Heat Biologics Basic Information, Area Served and Competitors
    Table 60. Heat Biologics Major Business
    Table 61. Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Product and Services
    Table 62. Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 63. Heat Biologics Recent Developments/Updates
    Table 64. Heat Biologics Competitive Strengths & Weaknesses
    Table 65. ImmunoCellular Therapeutics Basic Information, Area Served and Competitors
    Table 66. ImmunoCellular Therapeutics Major Business
    Table 67. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Services
    Table 68. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 69. ImmunoCellular Therapeutics Recent Developments/Updates
    Table 70. ImmunoCellular Therapeutics Competitive Strengths & Weaknesses
    Table 71. Immunicum Basic Information, Area Served and Competitors
    Table 72. Immunicum Major Business
    Table 73. Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Product and Services
    Table 74. Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 75. Immunicum Recent Developments/Updates
    Table 76. Immunicum Competitive Strengths & Weaknesses
    Table 77. MolecuVax Basic Information, Area Served and Competitors
    Table 78. MolecuVax Major Business
    Table 79. MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Product and Services
    Table 80. MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 81. MolecuVax Recent Developments/Updates
    Table 82. MolecuVax Competitive Strengths & Weaknesses
    Table 83. Northwest Biotherapeutics Basic Information, Area Served and Competitors
    Table 84. Northwest Biotherapeutics Major Business
    Table 85. Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Services
    Table 86. Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 87. Northwest Biotherapeutics Recent Developments/Updates
    Table 88. Northwest Biotherapeutics Competitive Strengths & Weaknesses
    Table 89. Pique Therapeutics Basic Information, Area Served and Competitors
    Table 90. Pique Therapeutics Major Business
    Table 91. Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Services
    Table 92. Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 93. Pique Therapeutics Recent Developments/Updates
    Table 94. Pique Therapeutics Competitive Strengths & Weaknesses
    Table 95. Regeneus Basic Information, Area Served and Competitors
    Table 96. Regeneus Major Business
    Table 97. Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Product and Services
    Table 98. Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 99. Regeneus Recent Developments/Updates
    Table 100. Regeneus Competitive Strengths & Weaknesses
    Table 101. Tessa Therapeutics Basic Information, Area Served and Competitors
    Table 102. Tessa Therapeutics Major Business
    Table 103. Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product and Services
    Table 104. Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 105. Tessa Therapeutics Recent Developments/Updates
    Table 106. Tessa Therapeutics Competitive Strengths & Weaknesses
    Table 107. Vaccinogen Basic Information, Area Served and Competitors
    Table 108. Vaccinogen Major Business
    Table 109. Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Product and Services
    Table 110. Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 111. Vaccinogen Recent Developments/Updates
    Table 112. XEME Biopharma Basic Information, Area Served and Competitors
    Table 113. XEME Biopharma Major Business
    Table 114. XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Product and Services
    Table 115. XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 116. Global Key Players of Dendritic Cell Cancer Vaccine Immunotherapy Upstream (Raw Materials)
    Table 117. Dendritic Cell Cancer Vaccine Immunotherapy Typical Customers
List of Figure
    Figure 1. Dendritic Cell Cancer Vaccine Immunotherapy Picture
    Figure 2. World Dendritic Cell Cancer Vaccine Immunotherapy Total Market Size: 2019 & 2023 & 2030, (USD Million)
    Figure 3. World Dendritic Cell Cancer Vaccine Immunotherapy Total Market Size (2019-2030) & (USD Million)
    Figure 4. World Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Region (2019, 2023 and 2030) & (USD Million) , (by Headquarter Location)
    Figure 5. World Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Region (2019-2030), (by Headquarter Location)
    Figure 6. United States Based Company Dendritic Cell Cancer Vaccine Immunotherapy Revenue (2019-2030) & (USD Million)
    Figure 7. China Based Company Dendritic Cell Cancer Vaccine Immunotherapy Revenue (2019-2030) & (USD Million)
    Figure 8. Europe Based Company Dendritic Cell Cancer Vaccine Immunotherapy Revenue (2019-2030) & (USD Million)
    Figure 9. Japan Based Company Dendritic Cell Cancer Vaccine Immunotherapy Revenue (2019-2030) & (USD Million)
    Figure 10. South Korea Based Company Dendritic Cell Cancer Vaccine Immunotherapy Revenue (2019-2030) & (USD Million)
    Figure 11. ASEAN Based Company Dendritic Cell Cancer Vaccine Immunotherapy Revenue (2019-2030) & (USD Million)
    Figure 12. India Based Company Dendritic Cell Cancer Vaccine Immunotherapy Revenue (2019-2030) & (USD Million)
    Figure 13. Dendritic Cell Cancer Vaccine Immunotherapy Market Drivers
    Figure 14. Factors Affecting Demand
    Figure 15. World Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 16. World Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Market Share by Region (2019-2030)
    Figure 17. United States Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 18. China Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 19. Europe Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 20. Japan Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 21. South Korea Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 22. ASEAN Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 23. India Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value (2019-2030) & (USD Million)
    Figure 24. Producer Shipments of Dendritic Cell Cancer Vaccine Immunotherapy by Player Revenue ($MM) and Market Share (%): 2023
    Figure 25. Global Four-firm Concentration Ratios (CR4) for Dendritic Cell Cancer Vaccine Immunotherapy Markets in 2023
    Figure 26. Global Four-firm Concentration Ratios (CR8) for Dendritic Cell Cancer Vaccine Immunotherapy Markets in 2023
    Figure 27. United States VS China: Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share Comparison (2019 & 2023 & 2030)
    Figure 28. United States VS China: Dendritic Cell Cancer Vaccine Immunotherapy Consumption Value Market Share Comparison (2019 & 2023 & 2030)
    Figure 29. World Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type, (USD Million), 2019 & 2023 & 2030
    Figure 30. World Dendritic Cell Cancer Vaccine Immunotherapy Market Size Market Share by Type in 2023
    Figure 31. Provenge
    Figure 32. Apceden
    Figure 33. CreaVax
    Figure 34. Others
    Figure 35. World Dendritic Cell Cancer Vaccine Immunotherapy Market Size Market Share by Type (2019-2030)
    Figure 36. World Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application, (USD Million), 2019 & 2023 & 2030
    Figure 37. World Dendritic Cell Cancer Vaccine Immunotherapy Market Size Market Share by Application in 2023
    Figure 38. Pediatrics
    Figure 39. Adults
    Figure 40. Dendritic Cell Cancer Vaccine Immunotherapy Industrial Chain
    Figure 41. Methodology
    Figure 42. Research Process and Data Source

Companies Mentioned

Lineage Cell Therapeutics
AVAX Technologies
DCPrime
Gradalis
Heat Biologics
ImmunoCellular Therapeutics
Immunicum
MolecuVax
Northwest Biotherapeutics
Pique Therapeutics
Regeneus
Tessa Therapeutics
Vaccinogen
XEME Biopharma